(19)
(11) EP 2 219 645 A2

(12)

(88) Date of publication A3:
27.08.2009

(43) Date of publication:
25.08.2010 Bulletin 2010/34

(21) Application number: 08851028.4

(22) Date of filing: 13.11.2008
(51) International Patent Classification (IPC): 
A61K 31/404(2006.01)
A61K 31/4439(2006.01)
A61K 45/06(2006.01)
A61P 11/06(2006.01)
A61P 37/08(2006.01)
A61K 31/405(2006.01)
A61K 31/4709(2006.01)
A61P 27/14(2006.01)
A61P 17/00(2006.01)
(86) International application number:
PCT/GB2008/003824
(87) International publication number:
WO 2009/063202 (22.05.2009 Gazette 2009/21)
(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR
Designated Extension States:
AL BA MK RS

(30) Priority: 13.11.2007 GB 0722203

(71) Applicant: Oxagen Limited
Oxfordshire OX14 4RY (GB)

(72) Inventors:
  • HUNTER, Michael, George
    Abingdon, Oxon OX14 4RY (GB)
  • PETTIPHER, Eric, Roy
    Abingdon, Oxon OX14 4RY (GB)
  • PERKINS, Colin, Michael
    Abingdon, Oxon OX14 4RY (GB)
  • Payton, Mark, Anthony
    Abingdon, Oxon OX14 4RY (GB)
  • XUE, Luzheng
    Abingdon, Oxon OX14 4RY (GB)

(74) Representative: Roberts, Alison Christine et al
Kilburn & Strode LLP 20 red Lion Street
London WC1R 4PJ
London WC1R 4PJ (GB)

   


(54) USE OF CRTH2 ANTAGONIST COMPOUNDS